S&P/ASX 200 Index (ASX: XJO) shares are just inside the green on Tuesday as the market awaits the next interest rate announcement at 2:30pm. 

Analysts are pricing in a 92% bet that the Reserve Bank of Australia (RBA) will lift the cash rate by 0.25% to 4.6%. 

Persistently high inflation, rising oil prices due to the Iran-US conflict, soaring bond yields to multi-decade highs, and rock-bottom productivity growth in Australia are among the reasons interest rates are expected to rise again.

Experts say there could even be another 0.25% bump in November, which would be the fifth in the 2026 calendar year. 

Meanwhile, experts offer their ratings and thoughts on three ASX 200 shares. 

Woodside Energy Group Ltd (ASX: WDS)

The Woodside share price is $31.21, down 1.8% today and up 33% over 12 months. 

John Athanasiou from Red Leaf Securities has a buy rating on this ASX 200 energy share. 

Athanasiou said (courtesy of The Bull): 

Woodside offers exposure to recent elevated global energy prices amid supply disruptions and continuing Middle East tensions.

Stronger realised prices should support near term cash flow and dividends.

A major risk is an easing of geopolitical tensions and a corresponding fall in crude oil prices.

However, the company delivered a solid interim result. Operating revenue of $7.446 billion in the first half of 2026 was up 13 per cent on the prior corresponding period. Underlying net profit after tax of $1.334 billion was up 7 per cent.

The Scarborough energy project is almost completed.

Ramsay Health Care Ltd (ASX: RHC)

The Ramsay Health Care share price is $55.77, up 0.4% today and up 77% over 12 months. 

Morgans has a hold rating on this ASX 200 healthcare share. 

The broker said: 

Ramsay Santé’s Capital Markets Day provided detail on its new “Connecting Care 2030” strategy ahead of the proposed demerger from RHC.

The strategy targets 2-3% revenue growth and stable EBITDA margins in FY27, followed by c3% revenue growth and gradual margin improvement to FY29.

While we view the strategy as credible, the outlook points to gradual rather than significant earnings growth, with tariff constraints remaining a key headwind.

For RHC shareholders, the proposed in-specie distribution should simplify the group and provide direct ownership of Santé through ASX-tradeable CDIs.

Life360 Inc (ASX: 360)

The Life360 share price is $18.95, down 1.9% today and down 64% over 12 months. 

Michael Gable from Fairmont Equities has a sell rating on this ASX 200 tech share. 

Gable commented: 

The company posted a 38 per cent increase in revenue in the second quarter of 2026 when compared to the prior corresponding period. Total subscription revenue was up 31 per cent.

However, the share price has fallen from $29.48 on August 10 to trade at $19.44 on September 24.

We believe the business is vulnerable to increasing competition. Any earnings disappointments moving forward may further pressure the share price.

Investors may want to consider cashing in some gains.

The post Buy, hold, sell: Woodside, Life360, Ramsay Health Care shares appeared first on The Motley Fool Australia.

More reading

• Sell alert! Why this expert is calling time on Life360 and Xero shares
• Expert names ‘undervalued’ ASX 200 healthcare stock to buy today
• Experts name 3 popular ASX 200 shares to buy this week
• TechnologyOne vs Life360: Which ASX tech share has more upside?
• Expert names Woodside and BHP shares as top buys today

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are just inside the green on Tuesday, up 0.04% to 8,683.4 points.

Among the 11 market sectors, technology is streaking ahead, up 4.4%, while energy is trailing the group, down 1.6%.

Let’s look at some new ratings from the experts (courtesy of The Bull).  

BHP Group Ltd (ASX: BHP)

The BHP share price is $60.36, up 0.9% today and up 44% over 12 months. 

Michael Gable from Fairmont Equities has a buy rating on this ASX mining share. 

Gable said: 

I believe commodities markets are in the early stages of a bull run, leaving BHP’s share price in a prime position to move higher.

Copper now generates most of BHP’s earnings after it produced almost 2 million tonnes in full year 2026. The company should also benefit from constrained global supplies of copper.

Iron ore is also a significant contributor to full year earnings. The company posted an attributable profit of $US9.8 billion in full year 2026, up 9 per cent on the prior corresponding period.

We view any share price dips as a buying opportunity.

JB Hi-Fi Ltd (ASX: JBH) 

The JB Hi-Fi share price is $66.95, up 1% today and down 43% over 12 months. 

Mark Gardner from MPC Markets has a hold rating on this ASX consumer discretionary share. 

Gardner said: 

JB Hi-Fi remains one of the better retailers on the ASX.

The consumer electronics giant delivered record sales of $11.06 billion in full year 2026, up 4.8 per cent on the prior corresponding period. Net profit after tax of $489.9 million was up 6 per cent. The total fully franked dividend of $3.37 was up 22.5 per cent.

A concern is momentum, as total sales growth for JB Hi-Fi Australia was down 0.5 per cent between July 1 and July 31, 2026.

Hold, but keep an eye on the news flow and numbers.

Corporate Travel Management Ltd (ASX: CTD)

The Corporate Travel Management share price is $2.37, up 1.7% today and up 2% over 12 months. 

John Athanasiou from Red Leaf Securities has a sell rating on this ASX retail share. 

Athanasiou said: 

CTD reported improved underlying earnings in fiscal year 2026. However, in my view, questions remain around historical customer remediation, governance, financial controls and funding requirements.

In a company update on April 22, 2026, a review had found that UK customers were charged in excess of their contractual entitlement.

On September 1, 2026, the company noted about 78 per cent of customer refunds had been agreed or were nearing finalisation.

In my view, the near term risk-reward equation remains unattractive.  

The post Buy, hold, sell: Corporate Travel Management, JB Hi-Fi, BHP shares appeared first on The Motley Fool Australia.

More reading

• BHP vs Coles: Which ASX share is better for passive income?
• Experts name 3 popular ASX 200 shares to buy this week
• 3 ASX shares to sell now according to experts
• Expert names Woodside and BHP shares as top buys today
• Should I buy BHP shares in October?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Corporate Travel Management. The Motley Fool Australia has positions in and has recommended Corporate Travel Management. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ResMed Inc. (ASX: RMD) share price is trading around $31.62 on Tuesday.

At that price, I think the sleep treatment company is starting to look cheap given the earnings growth expected over the next few years.

Here is why.

The earnings growth catches my attention

I think ResMed has a bright outlook that makes it worth considering today.

The company generated earnings per share (EPS) of $1.54 in FY26.

Consensus forecasts point to EPS increasing to $1.69 in FY27, $1.85 in FY28, and $2.02 in FY29.

That works out to annual earnings growth of roughly 9% to 10% across each of the next three years.

I think that is a very healthy pace for a business of ResMed’s size.

It means that at $31.62, the ResMed share price is trading on a PE ratio of roughly 18.7 times forecast FY27 earnings. That falls to around 17 times FY28 earnings and less than 16 times the FY29 estimate.

For a global healthcare company expected to compound earnings at close to double-digit rates, those numbers look quite reasonable to me.

Plenty of room to keep growing

The valuation is only attractive if the business has somewhere to go from here. I think ResMed does.

Sleep apnoea is a major global health problem with an estimated 1 billion+ sufferers, and a significant number of them remain undiagnosed or untreated.

That gives ResMed a substantial market opportunity as awareness improves and more patients enter the healthcare system.

The company is already one of the global leaders in sleep and respiratory care, with its devices helping patients manage obstructive sleep apnoea and other conditions.

That position means ResMed does not need to create an entirely new market. It can continue growing as diagnosis rates increase and treatment reaches a larger proportion of the people who could benefit from it.

I also think broader health trends support the long-term opportunity. Ageing populations and rising obesity rates can contribute to the prevalence of sleep apnoea, potentially increasing the number of people who require treatment over time.

So, is the ResMed share price cheap?

I think it is a cheap buy. A forward PE ratio below 19 times does not strike me as demanding when analysts expect earnings to grow at roughly 9% to 10% a year.

If ResMed reaches the FY29 EPS forecast of $2.02, today’s price would represent less than 16 times those earnings.

Of course, forecasts can change, and healthcare companies still need to execute well to turn market opportunity into earnings.

But at the current price, I think investors are getting a compelling risk/reward ratio.

Foolish takeaway

At $31.62, I think the ResMed share price looks cheap for the growth on offer.

With earnings expected to keep rising and the company still facing a large global market opportunity, I would be happy buying at current levels and holding for the long term.

The post Is the ResMed share price a cheap buy? appeared first on The Motley Fool Australia.

More reading

• 5 best ASX shares to buy in October
• How I’d build a $50,000 ASX share portfolio today
• 5 things to watch on the ASX 200 on Thursday
• How to build a $50,000 passive income from ASX shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.